Read the blog: https://ow.ly/CQpx50Sw2Ww Check out the latest AMCP Dossier Format Version 5.0. Learn about health disparities, real-world evidence, digital therapeutics, and more. Authors: Joshua Gauci, Irene Zahirovic (Zelner), PhD, Deepika Thakur #AMCP #HealthDisparities #RWE #DigitalTheraeutics
EVERSANA’s Post
More Relevant Posts
-
👏🏼👏🏼👏🏼 A big shoutout to Jordan Shlain, MD and Ken Rutkowski for sharing the latest and greatest in longevity medicine! Thank you 🙏🏼 for keeping us informed with non BS peer-reviewed therapies and therapeutics. If you're not already following Jordan, make sure to do so for expert insights and cutting-edge information. #LongevityMedicine #ExpertInsights #PeerReviewedTherapies
To view or add a comment, sign in
-
PharmaVoice breaks down the potentially seismic impacts of CRISPR-based therapies, with data from Norstella companies Citeline and Evaluate Ltd and commentary from Jen (Goldenberg) Klarer of The Dedham Group, where Jen underscores the promise and complexity of these treatments. Read the article here: https://ow.ly/pybG50QjgaM. #Pipeline2Patient #Norstella
To view or add a comment, sign in
-
Is the Surge in #DigitalBiomarker Adoption Reshaping #CardiovascularDisease Management? The increasing embrace of digital biomarkers among individuals grappling with chronic diseases, notably #cardiovascular conditions, is poised to propel market expansion. This innovative approach promises enhanced monitoring and personalized healthcare solutions, fostering a #transformative impact on managing and mitigating chronic ailments. As technology advances, the adoption of digital biomarkers becomes a pivotal driver in revolutionizing healthcare for a healthier future. Key Market Players: verily-life sciences, Clario, Feel Therapeutics, Sonde Health, Inc., Brainomix, AliveCor, Amgen., ActiGraph, Empatica, Explore the market overview: https://lnkd.in/dRyaGWRz #AMR #DigitalBiomarkers #HealthTechInnovation #CardiovascularHealth #ChronicDiseaseManagement #PersonalizedHealthcare #InnovativeHealthcare #PopulationHealth #DigitalHealthRevolution #HealthTechAdoption #FutureOfHealthcare
To view or add a comment, sign in
-
We are pleased to share our most recent publication, where we share the cost-effectiveness model we've developed to evaluate the efficacy and economic viability of Digital Variance Angiography (DVA) over Digital Subtraction Angiography (DSA) for lower limb x-ray angiography from the perspective of the English National Health Service (NHS). Utilizing a two-part economic model that integrates both a decision tree and a Markov model, this analysis delved into the financial and health outcomes related to the use of DVA, particularly its effects on the onset of acute kidney injury (AKI), chronic kidney disease, and radiation-induced cancer across a patient's lifetime. The model's base-case results revealed that DVA not only reduces costs by £309 per patient but also enhances quality-adjusted life years (QALYs) by 0.025. This improvement is attributed mainly to the diminished risk of contrast-associated AKI and a lower risk of developing carcinoma. The team at Optimax Access enjoyed collaborating with Kinepict Health Ltd. and Device Access UK Ltd teams, including Lorenzo Patrone. https://lnkd.in/evuqztTA The Evidence Base® Amir Ansaripour Mehdi Javanbakht (Ph.D.) Eoin Moloney #heor #healtheconomics #marketaccess #pharmaceuticals #costeffectiveness
To view or add a comment, sign in
-
Michalle Adkins discusses how today’s new therapies are more sophisticated and more targeted in comparison to the blockbuster one-size-fits-all medications of the past. Newer therapies are developed for specific patient populations, or cells used from an individual patient. Smaller batch sizes are required to meet the scale of these targeted therapies. Read article here: http://emr.as/5LXk50R0Teo #Emerson #lifesciences
To view or add a comment, sign in
-
Join Cardinal Health’s Fran Gregory, PharmD, MBA for a discussion on innovation in advanced therapies at #Asembia24. The session will explore how biosimilars can influence and improve future patient outcomes.
To view or add a comment, sign in
-
Join Cardinal Health’s Fran Gregory, PharmD, MBA for a discussion on innovation in advanced therapies at #Asembia24. The session will explore how biosimilars can influence and improve future patient outcomes.
Asembia AXS24 Summit | Cardinal Health
info.cardinalhealth.com
To view or add a comment, sign in
-
📢 The 2023 World Health Organization Pipeline analysis of Antibacterial Agents in Clinical and Preclinical development worldwide is out! As much as we can spot improvements, there is still a lot to be done. Even if the number of antibacterial agents in the clinical pipeline increased from 80 in 2021 to 97 in 2023, there is a pressing need for new, innovative agents for serious infections and to replace those becoming ineffective due to widespread use. Only together we can make a difference: let's pave the way to improve this report! Read the report here ➡ https://lnkd.in/eRy7Y8UP #amr #antibiotics
To view or add a comment, sign in
-
Director Practice Specialist: Clinical Tools, Data, and Informatics at Cardinal Health, Clinical Strategy and Technology Solutions
Join Cardinal Health’s Fran Gregory, PharmD, MBA for a discussion on innovation in advanced therapies at #Asembia24. The session will explore how biosimilars can influence and improve future patient outcomes.
Asembia AXS24 Summit | Cardinal Health
info.cardinalhealth.com
To view or add a comment, sign in
-
I recently came across an enlightening case study from Tria Health on the impact of pharmacogenomics in patient care, and I couldn't help but share! #Pharmacogenomics #PersonalizedMedicine #HealthcareInnovation #PatientCare #PGx https://lnkd.in/dhCUiNy7
Pharmacogenomics Case Study | Tria Health
triahealth.com
To view or add a comment, sign in
388,746 followers